Adopting foreign price controls would jeopardize access to new, innovative medicines for patients in need.
Because of the unique capital needs of groundbreaking research, growing biotech companies often turn to the public market for financing.
New Issue Brief on Co-Pay Accumulator Programs
During the 2018 PAHPA reauthorization process, Congress must continue to send a strong signal that it is committed to prioritizing health security by providing the resources needed to allow the nation to fully prepare for and defend against biological threats.
New, innovative treatments – “Transformative Therapies” – provide a significant, durable benefit and value for patient health outcomes, delivery of care, and overall healthcare spending.
Human genome editing is a process by which a DNA sequence is modified to elicit a desired outcome within a living cell.
Strong patents are the lifeblood of the biotechnology industry.
The Medicare prescription drug program - known as Medicare Part B - provides America's seniors and disabled individuals with access to a wide range of affordable medicines.
Learn about the Pharmaceutical Information Exchange Act of 2017 and its role in helping share information between biopharma innovators and population health decision makers.